Envestnet Asset Management
MRNA icon

Envestnet Asset Management’s Moderna MRNA Stock Holding History

Envestnet Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.93M Buy
41,770
+3,480
+9% +$180K ﹤0.01% 2869
2026
Q1 		$1.95M Buy
38,290
+11,936
+45% +$557K ﹤0.01% 3031
2025
Q4 		$777K Sell
26,354
-10,042
-28% -$273K ﹤0.01% 3413
2025
Q3 		$940K Buy
36,396
+19,826
+120% +$553K ﹤0.01% 3353
2025
Q2 		$457K Sell
16,570
-1,532
-8% -$40.3K ﹤0.01% 3759
2025
Q1 		$513K Sell
18,102
-12,212
-40% -$433K ﹤0.01% 3607
2024
Q4 		$1.26M Sell
30,314
-69,859
-70% -$3.34M ﹤0.01% 2998
2024
Q3 		$6.69M Sell
100,173
-9,560
-9% -$878K ﹤0.01% 1911
2024
Q2 		$13M Buy
109,733
+48,316
+79% +$6.11M ﹤0.01% 1386
2024
Q1 		$6.54M Buy
61,417
+17,760
+41% +$1.79M ﹤0.01% 1797
2023
Q4 		$4.34M Sell
43,657
-8,496
-16% -$715K ﹤0.01% 1993
2023
Q3 		$5.39M Sell
52,153
-116,284
-69% -$13M ﹤0.01% 1739
2023
Q2 		$20.5M Sell
168,437
-1,370,069
-89% -$183M 0.01% 916
2023
Q1 		$26.2M Buy
1,538,506
+1,346,028
+699% +$222M 0.01% 752
2022
Q4 		$34.6M Buy
192,478
+16,389
+9% +$2.68M 0.02% 595
2022
Q3 		$20.8M Buy
176,089
+20,869
+13% +$3.17M 0.01% 756
2022
Q2 		$22.2M Buy
155,220
+72,197
+87% +$10.3M 0.01% 743
2022
Q1 		$14.3M Buy
83,023
+20,121
+32% +$3.39M 0.01% 1018
2021
Q4 		$16M Buy
62,902
+16,084
+34% +$4.7M 0.01% 943
2021
Q3 		$18M Buy
46,818
+1,280
+3% +$472K 0.01% 847
2021
Q2 		$10.7M Buy
45,538
+460
+1% +$82.2K 0.01% 1092
2021
Q1 		$5.9M Buy
45,078
+18,102
+67% +$2.62M ﹤0.01% 1335
2020
Q4 		$2.82M Buy
26,976
+8,621
+47% +$872K ﹤0.01% 1560
2020
Q3 		$1.3M Buy
18,355
+7,752
+73% +$540K ﹤0.01% 1862
2020
Q2 		$681K Buy
+10,603
New +$581K ﹤0.01% 2208

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Envestnet Asset Management's MRNA Position: Q2 2026 in Review

Envestnet Asset Management increased its Moderna (MRNA) stake by 9.1% in Q2 2026, buying an estimated $180K and bringing the position to 41,770 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2869.

Envestnet Asset Management first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $34.6M in Q4 2022. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Envestnet Asset Management held 41,770 shares of Moderna worth $2.93M as of Q2 2026.
  • Envestnet Asset Management bought 3,480 Moderna shares in Q2 2026, an estimated $180K.
  • Moderna made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2869 holding.
  • Envestnet Asset Management first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Envestnet Asset Management's Moderna position peaked at $34.6M in Q4 2022.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.